Deaten

Quick links to important sections

Deaten

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deaten

Property Description
Active Ingredient Atomoxetine (as Hydrochloride)
Form Oral Capsule
Pharmacological Class Selective Norepinephrine Reuptake Inhibitor (SNRI)
Type Nonstimulant Medication
Origin Synthetic

The Identity and Composition of Deaten

Deaten is a prescription medication whose active substance is Atomoxetine, a synthetic compound typically formulated as Atomoxetine Hydrochloride. This oral capsule is recognized by official bodies as a single-ingredient product designed for systemic delivery. The chemical structure of Atomoxetine, particularly the R(-) isomer, is characterized by its potent and targeted effect on norepinephrine reuptake. The final preparation utilizes necessary pharmaceutical excipients to complement the active agent.

Deaten's Pharmacological Classification and Type

Deaten is classified as a Selective Norepinephrine Reuptake Inhibitor (SNRI), a key distinction of its pharmacological type. The mechanism centers on blocking the pre-synaptic norepinephrine transporter (NET), which enhances the availability of the neurotransmitter Norepinephrine (NE) in the synaptic space. Crucially, Atomoxetine is designated a nonstimulant drug, setting it apart from classic stimulant treatments and providing an important alternative for patient groups, including children and adolescents.

The General Purpose of Atomoxetine

Clinically recognized to modulate the brain's environment, the general therapeutic purpose of Atomoxetine is to support executive functions. By sustaining the necessary concentrations of Norepinephrine, the medication facilitates fundamental cognitive abilities. This targeted support results in improved concentration, greater sustained mental effort, and enhanced regulation of impulsive responses—all critical aspects of focused behavior.

Regulatory References

  1. NIH: Atomoxetine in Clinical Use

What side effects are possible with Deaten?

Possible Side Effects and Safety Information

Deaten (Active Ingredient: [Hypothetical Compound X]) is a medication used to treat [Hypothetical Condition Y]. As with all medications, it may cause side effects, though not everyone experiences them. It is important to discuss all potential risks and benefits with a healthcare professional before starting treatment.


Common Side Effects

Side effects that are most frequently reported and generally mild to moderate may include:

  • Gastrointestinal Distress: Nausea, vomiting, diarrhea, or constipation.
  • Nervous System Effects: Headache, dizziness, or mild fatigue.
  • Sleep Disturbances: Insomnia or unusual drowsiness.

If any of these common effects persist or worsen, you should consult your doctor.


Serious Side Effects

Though rare, certain serious adverse reactions require immediate medical attention. Seek emergency care if you experience:

  • Signs of Allergic Reaction: Rash, hives, swelling of the face, lips, tongue, or throat, or difficulty breathing.
  • Cardiovascular Issues: Chest pain, irregular heartbeat, or severe hypertension.
  • Hepatic Issues: Yellowing of the skin or eyes (jaundice), or persistent abdominal pain, which may indicate liver problems.

Safety Precautions and Monitoring

Deaten may interact with other medications, including over-the-counter drugs and herbal supplements. Inform your prescriber of all current medications to prevent adverse interactions. Regular monitoring of [relevant lab value, e.g., Liver Function Tests or Blood Pressure] may be necessary throughout treatment to ensure the drug is tolerated safely. Use caution when operating machinery or driving until you know how Deaten affects you.

Overdose and Emergency Response

Overdose Manifestations and Required Response

Any suspected overdose of Deaten (Atomoxetine) requires immediate medical attention. This guidance is mandated by official regulatory authorities due to the potential for serious systemic outcomes. Clinical manifestations reported in human experience include gastrointestinal symptoms (e.g., nausea, vomiting) and central nervous system effects such as somnolence (drowsiness), dizziness, tremor, and abnormal behavior. Signs of sympathetic nervous system activation, including tachycardia (increased heart rate) and increased blood pressure, have also been documented.


Severe Outcomes and Management

Severe outcomes reported in overdose cases include seizures and QT prolongation. While fatalities have been reported, these cases involved mixed ingestion overdose with atomoxetine and at least one other drug; deaths involving atomoxetine alone have not been noted.

Because no specific antidote is known, management focuses on administering symptomatic and supportive measures. Official labeling requires close monitoring of cardiac and vital signs and continuous observation until the patient achieves clinical stabilization. Supportive procedures such as gastric lavage and activated charcoal may be considered in a medical setting, though dialysis is typically ineffective due to the drug's protein-binding properties.

Therapeutic Uses of Deaten

Deaten (Atomoxetine) is commonly used to help manage the core symptomatic domains of Attention-Deficit/Hyperactivity Disorder (ADHD). The medication is considered relevant for easing persistent symptom clusters that create noticeable functional strain in daily life.

The core therapeutic application is the management of ADHD symptoms, which typically includes patterns of inattention, hyperactivity, and impulsivity. The medication is generally used in clinical contexts that require a long-term strategy for managing the chronic and pervasive nature of these symptoms in both pediatric populations (children and adolescents) and adults.

Supporting Focus and Behavioral Regulation

This therapeutic domain addresses inattention and difficulties completing tasks, which may assist with maintaining focus during academic, occupational, or complex daily activities. It is also applied in addressing symptoms of excessive motor activity and behavioral impulsivity, supporting the patient during difficult episodes by easing distress and helping to maintain functional stability in social settings. Its therapeutic application aims to ease the overall symptom load and support patients during episodes of heightened discomfort.


Quick Fact: Supports Management of Inattention, Hyperactivity, and Impulsivity

Eligibility and Restrictions for Use

Who can and cannot use Deaten (Atomoxetine)

The official eligibility profile for Atomoxetine is strictly defined by age, pre-existing conditions, and physiological status as mandated by regulatory authorities.

Category Official Regulatory Statement
Populations Allowed Approved for use in children 6 years of age and older, adolescents, and adults.
Absolute Contraindications Prohibited for use with Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of stopping one. Also contraindicated in patients with narrow-angle glaucoma, pheochromocytoma, hypersensitivity, or severe cardiovascular disorders.
Age-Related Rules Minimum age: 6 years. Use is not established in children under 6 or in older adults (over 65 years).
Conditional Restrictions Hepatic Insufficiency: A mandatory dose reduction (e.g., 50% for moderate, 75% for severe impairment) is required. Pregnancy/Lactation: Use is not recommended unless the benefit outweighs the potential risk.

Eligibility Classifications

  • Contraindicated: Applies to absolute prohibitions (e.g., Narrow-angle Glaucoma, MAOI use).
  • Not Established: Applies to populations lacking sufficient safety/efficacy data (e.g., children < 6, older adults).
  • Use with Caution: Applies to conditions requiring special monitoring (e.g., pre-existing hypertension, structural cardiac abnormalities).

The regulatory framework establishes who can or cannot use the medicine under its labeled conditions. Use is strictly forbidden for populations with absolute contraindications, such as severe heart conditions. Conditional restrictions, like required dose adjustments for liver impairment, further define the boundaries of use for specific patient groups.

What should I know about interactions with other medicines?

Deaten Interactions with other medicines and products

Drug interactions can alter how a medicine works, potentially increasing the risk of side effects or reducing its effectiveness. It is essential to discuss all medications, over-the-counter products, and supplements with a healthcare professional.

Authoritative medical and regulatory databases, including those managed by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), do not contain specific interaction information for a product officially designated as Deaten. Therefore, a complete regulatory-based interaction profile is not available under this name.

In the absence of specific drug labeling, general principles for drug-drug, drug-food, and drug-condition interactions apply, and caution should be exercised. Many medications are affected by other substances that either induce or inhibit liver enzymes, particularly the Cytochrome P450 (CYP) system, or by drugs that affect cellular drug transporters (e.g., P-glycoprotein).

Interaction Classifications

Category Note
Drug-Drug No specific interacting products or classes officially listed in regulatory documents.
Drug-Food/Beverage No specific restrictions listed in regulatory documents.
Drug-Condition No specific disease-related interactions listed in regulatory documents.

Any combination of medications should be assessed for potential additive effects (e.g., increased sedation) or competitive effects on elimination pathways. Individuals should notify their healthcare provider before initiating any new substance.

Mechanism of Action

Selective Norepinephrine Transporter Blockade

The core mechanism of Deaten is its highly selective action as a reuptake inhibitor on the Norepinephrine Transporter (NET). By binding to and blocking this presynaptic protein, the drug prevents the reabsorption of Norepinephrine (NE), a key neurotransmitter involved in alertness, into the nerve cell, thereby raising its concentration in the synaptic space. This engagement of the noradrenergic system supports the modulation of neural signaling within circuits responsible for attentional control.


Targeted Catecholamine Modulation in the Prefrontal Cortex

This mechanism uniquely results in a co-modulation of Dopamine (DA) levels, specifically confined to the Prefrontal Cortex (PFC), the brain's executive control center. This selectivity occurs because the NET, which Deaten inhibits, is the primary clearance pathway for Dopamine in the PFC. The targeted enhancement of both NE and DA in the PFC supports the functional connectivity within circuits governing response inhibition and executive control.


Mechanism-Dependent Onset Timecourse

The observed physiological effects of Deaten are not immediate because the underlying mechanism relies on the gradual adaptation of complex postsynaptic adrenoceptors and the functional normalization of brain circuits, not simply a rapid receptor activation. This requirement for chronic modulation and system-level adjustment dictates the delayed timecourse over which the functional adaptation of neural circuits is completed.

Dosage and Administration Information

How Deaten is Used

Deaten (Atomoxetine) is administered exclusively by the oral route using a capsule formulation. The capsule must be swallowed whole and must not be crushed, broken, chewed, or opened. This is a critical administration constraint to ensure proper drug delivery.


Official Dosing and Frequency

Administration is generally once daily or in two evenly divided doses taken in the morning and late afternoon/early evening. The medication may be taken with or without food.

Treatment is initiated with a lower dose, such as 40 mg once daily for adults and pediatric patients over 70 kg. Doses are then gradually adjusted (titrated) after a minimum interval of three days toward the target maintenance dose of 80 mg per day, with a maximum recommended total daily dose of 100 mg.


Population-Specific Adjustments

Dosage requires specific modification for certain populations. For pediatric patients weighing 70 kg or less, dosing is based on weight, starting at 0.5 mg/kg/day. For patients with moderate to severe hepatic (liver) impairment, the total initial and target doses must be reduced by 50% or 75%, respectively, based on the degree of impairment. A maximum daily dose of 80 mg is specified for individuals identified as CYP2D6 Poor Metabolizers. In the event a dose is missed, it should be taken as soon as possible, but double doses must not be taken to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Deaten


Evidence for Core ADHD Symptoms in Children and Adolescents

Research has extensively studied Deaten (Atomoxetine) in patients with the core symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. The primary evidence was observed in numerous short-term Randomized Controlled Trials (RCTs), where symptom changes were measured against a placebo (an inactive substance). These studies used in research exploring how symptoms change over time, relying on standardized clinician- and parent-rated scales to track changes in inattention, hyperactivity, and impulsivity.

Studies conducted during these defined time intervals reported patterns observed in the studies, showing the evaluation of scores in the symptom rating scores compared to the placebo groups. Following these initial trials, longer-term open-label extension studies were applied in research exploring how symptoms change over time. These extensions observed patients for intermediate periods to assess patterns observed following continuous use.

Research for ADHD in Adults

Deaten was studied for ADHD symptoms in adults. The available evidence primarily comes from short-term Randomized Controlled Trials (RCTs) and systematic reviews. Research examined the adult population, focusing on outcomes related to daily functioning and changes in symptom intensity. Symptomatic change was observed in trials using specialized patient-reported and investigator-rated scales.

Research describes the patterns observed in the studies, including the evaluation of scores in symptoms of inattention and hyperactivity/impulsivity compared to placebo. However, the evidence quality varies across studies, and the adult trials generally involved shorter follow-up durations (often around 10 to 12 weeks).

Studies in Comorbid Populations

Research has specifically explored Atomoxetine in patients with Attention-Deficit/Hyperactivity Disorder (ADHD) coexisting with Autism Spectrum Disorder (ASD). These studies were generally structured as short-term RCTs followed by open-label extension phases. In these populations, studies report how symptoms evolved in the observed populations, primarily focusing on the ADHD core symptoms.

Long-Term Data and Maintenance of Effect

Limited information for long-term outcomes comes primarily from open-label and naturalistic observational settings, which do not offer the same rigorous comparison as placebo-controlled trials. Long-term effects are not fully established regarding overall functional improvement across the lifespan. The available data show patterns related to the continuity of symptomatic patterns in many patients.

Key Limitations and Areas of Uncertainty

The body of research for Deaten has several areas where certainty remains low. For both adults and children, the follow-up durations were limited in the most methodologically rigorous RCTs. Comparative evidence is lacking for many research questions, such as the direct evaluation of Atomoxetine against other non-stimulant therapies in head-to-head trials over extended periods. Data for certain groups, including the elderly or pregnant populations, remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Deaten (FAQ)


Q: Does Deaten affect birth control pills?

Official prescribing information describes that there is no specific contraindication or interaction involving most hormonal birth control pills. However, regulatory agencies suggest general caution when co-administering with drugs that affect the body's CYP2D6 enzyme system. The treating healthcare provider can assess potential concerns based on the individual's specific health profile.


Q: Can I take Deaten if I have a history of kidney issues?

According to official regulatory documents, no specific adjustment to the prescribed dose is required for individuals who have kidney impairment, including those with end-stage renal disease (ESRD). Dosing guidelines focus primarily on adjustments related to liver impairment and body weight, rather than kidney function.


Q: Is it okay to drink coffee while taking Deaten?

Regulatory documents do not list a specific interaction between this medication and caffeine. Both Deaten and coffee can have effects that potentially increase heart rate and blood pressure. For this reason, regulatory information suggests caution is generally warranted, as additive effects could potentially occur.


Q: Does Deaten have a risk of dependence or addiction?

Atomoxetine, the active ingredient in Deaten, is officially classified by US regulatory bodies as an unscheduled or uncontrolled substance. This classification indicates that the drug has a low potential for abuse or physical dependence.


Q: Is Deaten sold under any other brand names?

Yes, the active ingredient, Atomoxetine, is available under its original brand name and may also be sold under various FDA-approved generic names. The active component remains the same regardless of whether the medicine is dispensed as a brand-name or generic product.


Q: Does Deaten cause weight gain or loss?

Official clinical studies indicate that weight loss is a reported side effect associated with this medication. A small number of patients across all age groups experienced a decrease in weight during the trials. For children and adolescents, the official guidance describes that weight and height monitoring throughout treatment is typically employed to track growth.


Q: How long does Deaten stay in the system after I stop taking it?

How long the drug stays in the system depends on an individual's metabolism, which is how the body processes the medication. For most people (known as extensive metabolizers), the half-life is approximately 5 to 5.2 hours. However, for a smaller subset of individuals (poor metabolizers), the half-life is significantly longer, ranging from 21.6 to 24 hours.


Q: Can Deaten cause mood changes or depression?

The FDA prescribing information for this medication includes a Boxed Warning regarding the increased risk of suicidal ideation, or thinking about suicide, primarily observed in children and adolescents during short-term studies. Additionally, reports of mood swings are listed as a possible side effect in official documents.


Q: Does Deaten interact with over-the-counter pain relievers like ibuprofen?

Official interaction checks do not indicate a known direct interaction between Deaten and common over-the-counter pain relievers such as ibuprofen. Official guidance highlights the importance of discussing all medications and supplements with a healthcare professional to check for any potential effects from combining substances.


Q: What is the official purpose of the black box warning (if any) for Deaten?

The drug carries an FDA Boxed Warning, which is a key safety communication on the label. The purpose of this warning is to notify patients and healthcare providers of the increased risk of suicidal ideation in children and adolescents that was observed in short-term clinical trials.


Q: Is Deaten available as a generic medicine?

Yes, the FDA has approved generic versions of Atomoxetine capsules for the treatment of its labeled condition. Generic medicines contain the same active ingredient and are required to meet the same quality standards as the original brand-name product.


Q: What happens if Deaten is taken with alcohol?

Regulatory information notes there is no known direct chemical interaction between Deaten and alcohol. However, official warnings and precautions indicate that combining the two substances may potentially worsen certain common side effects of the medication, such as dizziness, sleepiness, nausea, or vomiting.


Q: What does 'contraindicated' mean for Deaten?

In regulatory and medical terminology, a contraindication means the medication should not be used in certain situations or by specific patients because the risks significantly outweigh the potential benefits. For Deaten, this applies to absolute prohibitions such as current use of MAOIs or having narrow-angle glaucoma.

How should Deaten be stored and disposed of?

Deaten capsules must be stored strictly according to the official regulatory requirements to maintain product stability.

Storage & Disposal Scope

Scope Element Regulatory Requirement
Labeled storage temperature requirements Store at Controlled Room Temperature, between 20 C and 25 C (68 F and 77 F), with permitted fluctuations up to 30 C (86 F).
Light/moisture protection requirements Mandatory protection from moisture and protection from light.
Handling requirements Do not freeze. If a capsule is opened or broken, avoid contact with the powder and wash exposed areas immediately with water.
Disposal instructions Dispose of unused or expired product in accordance with local requirements (e.g., using official drug take-back programs).
Child-protection storage requirements Must be stored out of the sight and reach of children.

Resulting Storage & Disposal Structure

Official labeling mandates that Deaten must be stored within a specific room temperature range and kept tightly closed in its original container to prevent exposure to light and excess moisture. The medicine is not to be frozen. Crucially, the capsules must not be opened or broken, and any unused or expired product requires disposal via official methods, such as a drug take-back program, as required by governmental guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deaten found in:

A-Z Index: